Published in Gene Therapy Weekly, July 8th, 2004
"The ability of tumor cells to resist apoptosis-inducing signals by cytotoxic T cells may decide the success or failure of tumor elimination. An important effector of apoptosis is the CD95/CD95 ligand system (APO-1/Fas) that mediates perforin-independent cytotoxic T-cell killing of tumor cells. We propose a new strategy by which tumor cells can resist CD95-induced apoptosis," scientists in Germany report.
"We identified matrix metalloproteinase-7, MMP-7 (Martilysin), as the first physiologically relevant protease that can specifically cleave CD95. MMP-7 is of unique importance...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.